ECF-2025-live Program 11.12.25

1. What are the main mechanisms of the pro-remyelinating contribution of microglia?*

a. Phagocytosis of myelin debrisb. Switch to Schwann cellsc. Secretion of pro-regenerative growth factors and cytokinesd. Modulation of the extracellular matrixe. Transformation into lymphocytesf. Synthesis of sterols from damaged myeling. Switch from neurodegenerative to remyelinating phenotype

2. The 2024 McDonald have added the following MRI metrics:*

a. Central vein signb. Paramagnetic rim lesionsc. Both A & Bd. None of the above

3. The 2024 McDonald have added:*

a. No new topographiesb. Optic nerve as a fifth topographyc. Lumbar roots as a fifth topographyd. Brachial plexus as a fifth topography

4. Worsening in multiple sclerosis occurs by which of the following mechanisms?*

a. Incomplete recovery from a relapseb. Gradual worsening in the absence of a relapsec. Both A & Bd. Neither A nor B

5. The following is correct in the context of MS immune pathophysiology:*

a. Relapsing MS biology transitions into progressive MS biologyb. Antibodies are now viewed as key contributors to relapsing MS biologyc. Infiltrating macrophage are major drivers of progressive MS biologyd. None of the above

6. Which of the following is a best practice to approach MS symptom management?*

a. Multi-disciplinary approachb. Identify and treat comorbid conditions that may affect symptomsc. Prioritize symptoms which most affect quality of lifed. Attempt non-pharmacological approaches before medicationse. All of the above

7. When using the central vein sign (CVS) to diagnose MS, when is "Select 6" considered positive?*

a. Less than 6 lesions should show the CVSb. 6 or more lesions should show the CVSc. When there are less than 10 lesions present, > 50% of white matter lesions should show the CVSd. Both B & Ce. None of the above

8. All of the following are TRUE concerning biosimilars, EXCEPT ONE. Choose the FALSE statement:*

a. Biosimilars need not be identical to reference drugs, just comparableb. Equivalence in efficacy still needs to be demonstrated with reference DMTc. Non-inferiority studies are not acceptable for demonstrating equivalenced. Studies of biosimilars need not use the same endpoints as the reference drug trialse. Non-biologic complex drugs are neither generics nor biosimilars

EVALUATION FORM
A Call to Action for the MS Specialists – Update Your Practice to Improve Patient Outcomes
Advanced Curriculum for Multiple Sclerosis 2025 CME Course
Wednesday, November 12th, 2025

AcademicCME appreciates your opinions to help assist us in the evaluation of the effectiveness of this activity and to identify your ongoing educational needs. Learners must complete this evaluation form to receive acknowledgement for completing this activity.

Name*

First NameLast Name

Email*

example@example.com

Which of the following best describes your title?*

MDPA/NPIndustryOther

How many years have you been in practice?

How many patients with multiple sclerosis do you typically see each month?

Do you feel this activity was fair balanced and free of commercial bias?

YesNo

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

YesNoN/A

This educational activity will result in a change in my practice behavior.

YesNoN/A

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team

What topics would you like to see at future Advanced Curriculum in MS programs?

Date

Attestation to time spent on activity:
This activity is certified for a maximum of 6.0 AMA PRA Category 1 Credits™.

I participated in this activity and claim _______ credit(s).*

PRE-TEST QUESTIONNAIRE

POST-TEST ASSESSMENT